Hub : Traits :

Worry (Nagel 2018)

935 significantly associated models · 142 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	117211384	118766534	1	1	1.7e-07	5.4e-09	2.8e-04	61	MAN1A2
2	1	153241677	154640423	1	1	5.6e-08	5.4e-07	1.4e-04	42	CREB3L4
3	1	226371939	227873074	2	1	6.6e-09	3.8e-08	4.2e-01	98	ADCK3
4	2	86483021	87126250	1	1	3.0e-07	1.4e-07	9.2e-02	90	VPS24
5	2	147993969	149475737	2	1	4.1e-11	7.7e-10	1.3e-01	94	ORC4L
6	3	16154636	17814553	1	1	1.2e-07	3.2e-06	2.0e-01	92	PLCL2
7	3	49598064	51398958	10	1	6.5e-11	1.9e-11	1.0e+00	100	U73166.2
8	3	51539688	54077726	20	1	5.5e-15	4.8e-12	1.4e-01	96	NEK4
9	3	84317575	86808226	1	1	2.9e-18	2.1e-19	1.0e+00	100	CADM2
10	3	135273949	137261517	5	1	5.2e-12	1.9e-11	4.7e-01	99	RP11-85F14.5
11	4	89947254	91439574	1	1	1.4e-09	2.6e-10	1.0e+00	100	SNCA
12	4	118707160	119423789	1	1	5.4e-09	1.7e-07	4.7e-02	86	NDST3
13	5	64272107	65711805	1	1	2.1e-07	7.5e-07	2.5e-01	94	SGTB
14	5	86867897	88429077	4	1	6.8e-10	3.6e-10	1.0e-04	62	TMEM161B
15	5	101762909	103244640	1	1	2.7e-08	1.4e-08	1.9e-01	95	PPIP5K2
16	8	9593924	10988275	1	1	9.6e-08	5.2e-09	1.5e-03	70	RP11-981G7.1
17	9	85627408	87026235	1	1	4.6e-08	6.3e-07	4.7e-02	84	RP11-522I20.3
18	9	95502571	96898436	1	1	8.2e-10	4.2e-09	3.8e-01	98	RP11-165J3.6
19	9	97520168	98975128	1	1	1.8e-08	5.7e-08	4.5e-01	98	PTCH1
20	9	127218258	128643415	2	1	1.2e-07	2.2e-07	1.0e+00	100	PRPS1P2
21	10	103550604	105910221	11	2	9.9e-14	2.9e-13	6.6e-01	100	AS3MT CALHM2
22	11	46578400	48559571	8	1	9.6e-14	3.3e-11	9.5e-01	100	MADD
23	11	112486568	113969669	3	2	6.6e-09	1.2e-09	3.7e-02	88	ANKK1 DRD2
24	12	49065727	50619618	1	1	2.8e-07	1.8e-06	7.2e-01	99	SPATS2
25	12	108763672	110704487	3	1	2.8e-10	2.4e-10	1.6e-01	95	MMAB
26	14	74424938	76239834	7	1	9.7e-14	1.2e-13	4.8e-03	86	RPS6KL1
27	16	29412503	31860399	15	2	4.2e-11	1.6e-08	2.0e-01	95	INO80E KAT8
28	17	19142226	20911204	3	1	7.2e-09	6.7e-08	1.5e-01	93	RP11-78O7.2
29	17	42607368	45796313	20	1	1.9e-14	8.6e-14	4.3e-01	99	MAPT
30	17	78843139	79380547	1	1	7.1e-09	2.2e-09	5.1e-02	89	AATK
31	18	30921425	31568499	1	1	8.8e-08	3.3e-08	1.0e-01	91	ASXL3
32	18	57349900	58729694	1	1	8.0e-08	4.9e-13	4.8e-07	52	MC4R
33	20	2496120	3897014	1	1	1.4e-07	5.0e-07	1.3e-02	76	ITPA
34	20	17776692	19441650	4	1	5.1e-09	1.1e-08	1.0e+00	100	DTD1
35	20	32594714	34109427	1	1	4.5e-09	2.8e-06	4.7e-01	98	NCOA6
36	22	40472399	42379813	3	1	5.4e-11	2.7e-10	4.5e-01	99	SLC25A17

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Neuroticism (Nagel 2018)	14.5	33	19	42.2	0.97	9.0e-21	AATK ADCK3 ANKK1 AS3MT ASXL3 CADM2 CALHM2 DRD2 DTD1 ITPA KAT8 MADD MAPT MC4R MMAB NCOA6 NDST3 NEK4 ORC4L PLCL2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RP11-981G7.1 RPS6KL1 SGTB SLC25A17 SNCA SPATS2 TMEM161B U73166.2 VPS24
Neuroticism	13.8	33	24	53.3	0.97	9.2e-21	AATK ADCK3 ANKK1 AS3MT ASXL3 CADM2 CALHM2 DRD2 DTD1 KAT8 MADD MAN1A2 MAPT MC4R MMAB NCOA6 NDST3 NEK4 ORC4L PLCL2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RP11-981G7.1 RPS6KL1 SGTB SLC25A17 SNCA SPATS2 TMEM161B U73166.2 VPS24
Neuroticism score	12.1	24	15	33.3	0.99	1.3e-18	AATK ADCK3 ANKK1 ASXL3 DRD2 DTD1 MADD MAPT MC4R MMAB NCOA6 NDST3 ORC4L PLCL2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RPS6KL1 SLC25A17 SNCA TMEM161B U73166.2 VPS24
Nervous feelings	11.6	23	12	26.7	0.99	8.9e-22	ADCK3 ANKK1 AS3MT ASXL3 CADM2 CALHM2 CREB3L4 DTD1 INO80E ITPA KAT8 MADD MAPT NCOA6 NEK4 ORC4L PRPS1P2 RP11-85F14.5 RPS6KL1 SLC25A17 SNCA TMEM161B U73166.2
Worrier / anxious feelings	11.2	24	10	22.2	0.99	2.6e-22	ADCK3 AS3MT CADM2 DTD1 INO80E KAT8 MAN1A2 MAPT MC4R MMAB NCOA6 NDST3 NEK4 ORC4L PLCL2 PPIP5K2 PRPS1P2 PTCH1 RP11-165J3.6 RP11-85F14.5 RPS6KL1 SLC25A17 TMEM161B U73166.2
Suffer from 'nerves'	10.0	14	4	8.9	0.98	2.2e-09	AATK ANKK1 AS3MT CADM2 DTD1 INO80E KAT8 MADD MAN1A2 MAPT MC4R NEK4 RP11-78O7.2 RPS6KL1
Tense / 'highly strung'	9.6	20	2	4.4	0.99	3.8e-16	AATK ADCK3 ANKK1 CADM2 CREB3L4 DRD2 DTD1 INO80E KAT8 MAPT NCOA6 NEK4 ORC4L RP11-165J3.6 RP11-78O7.2 RP11-85F14.5 RPS6KL1 SGTB SLC25A17 U73166.2
Depressed Affect (Nagel 2018)	7.6	15	9	20.0	0.98	1.4e-10	AATK ANKK1 ASXL3 DRD2 MADD MAPT MMAB ORC4L PLCL2 PTCH1 RP11-165J3.6 RP11-85F14.5 RPS6KL1 SNCA TMEM161B
Sensitivity / hurt feelings	7.6	11	3	6.7	0.97	6.4e-07	ANKK1 DRD2 MAPT MMAB NDST3 ORC4L PLCL2 PTCH1 RP11-165J3.6 RP11-85F14.5 TMEM161B
Mood swings	7.0	9	6	13.3	0.99	1.6e-07	ANKK1 ASXL3 DRD2 MADD MAPT PLCL2 RPS6KL1 SLC25A17 SNCA
Neuroticism (2016)	6.8	5	1	2.2	1.00	1.4e-04	DRD2 MADD MAPT SLC25A17 U73166.2
Frequency of tenseness / restlessness in last 2 weeks	6.7	7	2	4.4	0.99	2.0e-05	AATK DRD2 MAPT MMAB NEK4 RP11-165J3.6 RP11-85F14.5
Worry too long after embarrassment	6.7	8	3	6.7	0.98	2.8e-05	ANKK1 DRD2 MAPT MMAB NCOA6 PRPS1P2 RP11-85F14.5 SPATS2
Miserableness	5.9	8	3	6.7	0.98	1.2e-05	ANKK1 DRD2 MADD MAPT MMAB NDST3 ORC4L RP11-165J3.6
Depression (Nagel 2018)	5.8	9	1	2.2	0.99	2.0e-07	AATK ANKK1 MADD MAPT PLCL2 RP11-165J3.6 RP11-85F14.5 SNCA U73166.2
Guilty feelings	5.7	8	3	6.7	0.98	8.5e-06	AATK ANKK1 DRD2 MADD MAPT PTCH1 RPS6KL1 SPATS2
Frequency of depressed mood in last 2 weeks	5.5	9	0	0.0	1.00	5.9e-09	AATK ANKK1 DRD2 MADD MAPT PLCL2 RP11-165J3.6 RP11-85F14.5 U73166.2
Seen doctor (GP) for nerves, anxiety, tension or depression	5.5	6	1	2.2	0.99	1.9e-04	ANKK1 ASXL3 DRD2 RPS6KL1 SGTB TMEM161B
Irritability	5.4	7	3	6.7	0.99	3.5e-06	ANKK1 DRD2 MAPT MMAB NCOA6 ORC4L SLC25A17
Tanning	5.1	3	2	4.4	0.00	1.0e+00	CADM2 NCOA6 NEK4
Frequency of tiredness / lethargy in last 2 weeks	4.8	4	2	4.4	1.00	4.3e-03	AATK MMAB ORC4L RP11-165J3.6
Fed-up feelings	4.5	7	4	8.9	0.99	6.0e-06	DRD2 MADD MAPT ORC4L PLCL2 RP11-85F14.5 RPS6KL1
Schizophrenia (2014)	4.2	7	3	6.7	0.97	2.8e-04	AS3MT DRD2 INO80E NEK4 PLCL2 RP11-85F14.5 SLC25A17
Seen a psychiatrist for nerves, anxiety, tension or depression	4.2	1	0	0.0	0.00	1.0e+00	SGTB
Smoking Status	4.0	6	3	6.7	-0.33	5.2e-01	AATK AS3MT CADM2 NEK4 PLCL2 PRPS1P2
Frequency of unenthusiasm / disinterest in last 2 weeks	4.0	3	0	0.0	0.00	1.0e+00	DRD2 RP11-85F14.5 U73166.2
Schizophrenia (2018)	3.9	5	2	4.4	0.96	8.1e-03	AS3MT INO80E NEK4 RP11-85F14.5 SLC25A17
Bipolar Disorder or Schizophrenia	3.8	6	4	8.9	0.98	7.0e-04	AS3MT INO80E NDST3 NEK4 PLCL2 SLC25A17
Comparative body size at age 10	3.8	5	4	8.9	-0.98	2.8e-03	CADM2 MADD MC4R RP11-165J3.6 U73166.2
Loneliness, isolation	3.6	3	1	2.2	0.00	1.0e+00	MADD MAPT ORC4L
Alcohol intake frequency.	3.5	6	5	11.1	-0.37	4.7e-01	CADM2 DRD2 INO80E MADD MAPT TMEM161B
Impedance of whole body	3.5	10	9	20.0	0.75	1.3e-02	ADCK3 AS3MT CADM2 INO80E MAPT MC4R NCOA6 NEK4 PRPS1P2 U73166.2
BMI	3.4	10	7	15.6	-0.84	2.1e-03	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R NEK4 RP11-165J3.6 VPS24
Impedance of leg (right)	3.4	13	8	17.8	0.72	5.3e-03	ADCK3 AS3MT CADM2 INO80E MADD MAPT MC4R NCOA6 NEK4 PRPS1P2 PTCH1 RPS6KL1 U73166.2
Impedance of leg (left)	3.3	12	9	20.0	0.82	1.1e-03	ADCK3 AS3MT CADM2 INO80E MADD MAPT MC4R NCOA6 NEK4 PRPS1P2 RPS6KL1 U73166.2
Waist circumference	3.3	7	5	11.1	-0.84	1.9e-02	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R
Leg fat-free mass (left)	3.2	7	7	15.6	-0.73	6.1e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Leg predicted mass (left)	3.2	7	7	15.6	-0.73	6.1e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Hair/balding pattern: Pattern 4	3.2	1	1	2.2	0.00	1.0e+00	MAPT
Leg fat-free mass (right)	3.2	7	7	15.6	-0.72	6.8e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Leg predicted mass (right)	3.2	7	7	15.6	-0.72	6.8e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1
Basal metabolic rate	3.2	9	7	15.6	-0.75	2.0e-02	AS3MT CADM2 INO80E KAT8 MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Body mass index (BMI)	3.1	8	5	11.1	-0.93	8.6e-04	AS3MT CADM2 INO80E KAT8 MADD MC4R NEK4 VPS24
Past tobacco smoking	3.1	3	2	4.4	0.00	1.0e+00	AS3MT CADM2 PRPS1P2
Weight	3.1	8	5	11.1	-0.86	6.6e-03	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R TMEM161B
Impedance of arm (right)	3.1	11	6	13.3	0.73	1.0e-02	ADCK3 CADM2 INO80E MAPT MC4R NCOA6 NEK4 PRPS1P2 RP11-522I20.3 TMEM161B U73166.2
Hip circumference	3.1	7	6	13.3	-0.78	3.7e-02	AS3MT CADM2 INO80E KAT8 MADD MC4R PTCH1
Impedance of arm (left)	3.1	9	6	13.3	0.71	3.3e-02	CADM2 INO80E MAPT MC4R NEK4 PRPS1P2 RP11-78O7.2 TMEM161B U73166.2
Arm fat-free mass (right)	3.1	8	6	13.3	-0.77	2.6e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Whole body fat-free mass	3.1	9	7	15.6	-0.72	2.9e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RPS6KL1 TMEM161B
Smoking status: Current	3.1	2	1	2.2	0.00	1.0e+00	AATK AS3MT
Whole body water mass	3.1	9	7	15.6	-0.72	2.9e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RPS6KL1 TMEM161B
Arm fat mass (left)	3.1	8	6	13.3	-0.84	9.7e-03	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R VPS24
Arm fat-free mass (left)	3.1	8	5	11.1	-0.76	2.9e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Arm predicted mass (left)	3.1	8	7	15.6	-0.76	2.9e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Systolic Blood Pressure	3.0	9	6	13.3	0.63	7.0e-02	AS3MT CADM2 CALHM2 MADD MAPT ORC4L PRPS1P2 RP11-78O7.2 RPS6KL1
Hand grip strength (left)	3.0	7	3	6.7	-0.40	3.7e-01	ADCK3 AS3MT CADM2 INO80E MADD MAPT RPS6KL1
Current tobacco smoking	3.0	4	1	2.2	0.61	3.9e-01	AATK AS3MT PRPS1P2 SLC25A17
Trunk fat-free mass	3.0	10	7	15.6	-0.75	1.2e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RP11-78O7.2 RPS6KL1 TMEM161B
Arm fat mass (right)	3.0	8	5	11.1	-0.83	1.0e-02	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R VPS24
Trunk predicted mass	3.0	10	7	15.6	-0.75	1.2e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 RP11-78O7.2 RPS6KL1 TMEM161B
Medication for pain relief, constipation, heartburn	3.0	3	1	2.2	0.00	1.0e+00	MAPT RP11-165J3.6 RPS6KL1
Arm predicted mass (right)	3.0	8	6	13.3	-0.77	2.4e-02	AS3MT CADM2 INO80E MC4R NCOA6 PRPS1P2 PTCH1 TMEM161B
Ever smoked	3.0	4	1	2.2	-0.70	3.0e-01	AATK AS3MT CADM2 NEK4
Leg fat mass (left)	3.0	8	6	13.3	-0.84	8.9e-03	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R TMEM161B
Medication: Paracetamol	2.9	1	1	2.2	0.00	1.0e+00	MAPT
Headache pain in last month	2.9	1	1	2.2	0.00	1.0e+00	MAPT
Leg fat mass (right)	2.9	9	6	13.3	-0.84	4.7e-03	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R TMEM161B VPS24
Whole body fat mass	2.8	7	6	13.3	-0.84	1.7e-02	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MC4R
Overall health rating	2.8	3	0	0.0	0.00	1.0e+00	AATK ANKK1 RP11-165J3.6
Risk taking	2.8	2	1	2.2	0.00	1.0e+00	CADM2 RP11-85F14.5
Waist Hip Ratio (WHR)	2.7	7	5	11.1	0.77	4.1e-02	MAPT NEK4 PLCL2 PPIP5K2 PRPS1P2 RP11-85F14.5 U73166.2
Lung FVC	2.7	4	2	4.4	0.27	7.3e-01	KAT8 MAPT PTCH1 U73166.2
Number of incorrect matches in round	2.7	3	0	0.0	0.00	1.0e+00	AS3MT INO80E NDST3
Arm fat percentage (right)	2.7	7	4	8.9	-0.78	3.9e-02	ANKK1 INO80E KAT8 MADD MC4R RP11-165J3.6 VPS24
Arm fat percentage (left)	2.7	5	4	8.9	-0.80	1.1e-01	ANKK1 INO80E KAT8 MADD MC4R
Bipolar Disorder (2018)	2.6	1	0	0.0	0.00	1.0e+00	NEK4
Hair Pigment	2.6	3	3	6.7	0.00	1.0e+00	ADCK3 NCOA6 SLC25A17
Trunk fat mass	2.6	8	5	11.1	-0.85	7.3e-03	ANKK1 AS3MT CADM2 INO80E KAT8 MADD MAPT MC4R
Forced vital capacity (FVC)	2.6	3	2	4.4	0.00	1.0e+00	MAPT NDST3 PTCH1
Ever unenthusiastic/disinterested for a whole week	2.6	1	0	0.0	0.00	1.0e+00	MAPT
Neck or shoulder pain in last month	2.6	1	1	2.2	0.00	1.0e+00	ASXL3
Pain experienced in last month	2.6	2	0	0.0	0.00	1.0e+00	MAPT MMAB
Body Mass Index (BMI) (2010)	2.5	2	1	2.2	0.00	1.0e+00	MADD MC4R
Relative age of first facial hair	2.5	1	1	2.2	0.00	1.0e+00	MAPT
Taking other prescription medications	2.5	1	1	2.2	0.00	1.0e+00	RPS6KL1
Fluid intelligence score	2.5	3	0	0.0	0.00	1.0e+00	MAPT PLCL2 PPIP5K2
Medication: Paracetamol	2.5	1	1	2.2	0.00	1.0e+00	MAPT
Intelligence (Savage-Jansen 2018)	2.4	6	2	4.4	-0.80	5.6e-02	AATK MAPT NEK4 PLCL2 PPIP5K2 RP11-85F14.5
Verbal and Numeric Reasoning (VNR)	2.4	4	2	4.4	-0.99	5.5e-03	MAPT NEK4 PLCL2 PPIP5K2
Bipolar Disorder (2011)	2.4	1	0	0.0	0.00	1.0e+00	NEK4
Blood Red Count	2.4	9	6	13.3	0.73	2.6e-02	DRD2 INO80E KAT8 MAPT NCOA6 NEK4 PLCL2 PPIP5K2 TMEM161B
Number of treatments/medications taken	2.4	1	1	2.2	0.00	1.0e+00	RPS6KL1
Trunk fat percentage	2.4	8	5	11.1	-0.43	2.9e-01	ANKK1 INO80E KAT8 MADD MAPT MC4R RPS6KL1 SLC25A17
Hand grip strength (right)	2.4	5	2	4.4	-0.56	3.3e-01	CADM2 INO80E MADD MAPT NDST3
Forced expiratory volume in 1-second (FEV1)	2.4	3	2	4.4	0.00	1.0e+00	MAPT NDST3 PTCH1
Forced vital capacity (FVC), Best measure	2.4	2	2	4.4	0.00	1.0e+00	MAPT PTCH1
Body fat percentage	2.4	6	4	8.9	-0.45	3.7e-01	ANKK1 INO80E KAT8 MADD MC4R RPS6KL1
Leg fat percentage (right)	2.4	10	5	11.1	-0.42	2.2e-01	ANKK1 CADM2 INO80E KAT8 MADD MC4R NDST3 RP11-165J3.6 RPS6KL1 VPS24
Smoking status: Previous	2.4	1	1	2.2	0.00	1.0e+00	CADM2
Leg fat percentage (left)	2.4	9	4	8.9	-0.40	2.9e-01	ANKK1 CADM2 INO80E KAT8 MADD MC4R NDST3 RP11-165J3.6 RPS6KL1
Systolic blood pressure, automated reading	2.3	4	2	4.4	0.54	4.6e-01	AS3MT MADD MAPT PRPS1P2
Hearing difficulty/problems with background noise	2.3	1	1	2.2	0.00	1.0e+00	MAPT
Prospective memory result	2.3	1	0	0.0	0.00	1.0e+00	PLCL2
Health satisfaction	2.3	1	0	0.0	0.00	1.0e+00	DRD2
Relative age voice broke	2.2	1	1	2.2	0.00	1.0e+00	MAPT
Age when periods started (menarche)	2.2	4	2	4.4	0.49	5.1e-01	INO80E MADD MAPT NEK4
Hair/balding pattern: Pattern 3	2.2	1	1	2.2	0.00	1.0e+00	MAPT
Peak expiratory flow (PEF)	2.2	2	1	2.2	0.00	1.0e+00	MAPT NDST3
Fasting Glucose	2.1	1	1	2.2	0.00	1.0e+00	MADD
Chest pain or discomfort	2.1	1	0	0.0	0.00	1.0e+00	ASXL3
Alzheimer’s Disease (including proxy)	2.0	2	0	0.0	0.00	1.0e+00	KAT8 MADD
Age at First Birth	2.0	1	0	0.0	0.00	1.0e+00	CREB3L4
Forced expiratory volume in 1-second (FEV1), Best measure	2.0	2	1	2.2	0.00	1.0e+00	MAPT PTCH1
Qualifications: College or University degree	2.0	4	1	2.2	-0.03	9.7e-01	CADM2 MAPT PPIP5K2 TMEM161B
Mouth/teeth dental problems: Mouth ulcers	2.0	1	1	2.2	0.00	1.0e+00	MAPT
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.0	1	1	2.2	0.00	1.0e+00	MAPT
Average weekly champagne plus white wine intake	2.0	1	0	0.0	0.00	1.0e+00	MAPT
HDL Cholesterol	1.9	1	1	2.2	0.00	1.0e+00	MMAB
Sitting height	1.9	6	4	8.9	0.02	9.7e-01	AATK MADD MAPT NCOA6 NEK4 PTCH1
Financial difficulties in last 2 years	1.9	1	0	0.0	0.00	1.0e+00	DRD2
Number of live births	1.9	2	0	0.0	0.00	1.0e+00	CADM2 MAPT
Mouth/teeth dental problems: Dentures	1.9	1	0	0.0	0.00	1.0e+00	ADCK3
Birth weight	1.9	2	1	2.2	0.00	1.0e+00	AS3MT PTCH1
Average weekly red wine intake	1.9	1	0	0.0	0.00	1.0e+00	TMEM161B
Ovarian Cancer	1.8	1	1	2.2	0.00	1.0e+00	MAPT
Coronary Artery Disease (CAD)	1.8	1	0	0.0	0.00	1.0e+00	AS3MT
Lung FEV1/FVC ratio	1.8	6	2	4.4	-0.50	3.1e-01	ADCK3 INO80E KAT8 MAPT PTCH1 RPS6KL1
Qualifications: None of the above	1.8	3	1	2.2	0.00	1.0e+00	PLCL2 RP11-78O7.2 TMEM161B
Basal cell carcinoma (self-reported)	1.8	1	0	0.0	0.00	1.0e+00	NCOA6
Chronotype (morning person)	1.7	2	1	2.2	0.00	1.0e+00	TMEM161B U73166.2
Diabetes (father)	1.7	1	0	0.0	0.00	1.0e+00	INO80E
Maternal smoking around birth	1.7	1	0	0.0	0.00	1.0e+00	AS3MT
Hair/balding pattern: Pattern 2	1.7	1	0	0.0	0.00	1.0e+00	MAPT
Medication: Ibuprofen (e.g. Nurofen)	1.7	1	0	0.0	0.00	1.0e+00	MAPT
Qualifications: O levels/GCSEs or equivalent	1.7	1	0	0.0	0.00	1.0e+00	PLCL2
Number of children fathered	1.7	1	1	2.2	0.00	1.0e+00	CADM2
Age at last live birth	1.7	1	0	0.0	0.00	1.0e+00	DTD1
Triglycerides	1.6	1	0	0.0	0.00	1.0e+00	NCOA6
Height	1.6	19	13	28.9	-0.16	5.1e-01	AATK AS3MT CREB3L4 INO80E KAT8 MADD MAPT MC4R NCOA6 NDST3 NEK4 ORC4L PPIP5K2 PTCH1 RP11-165J3.6 RP11-522I20.3 RPS6KL1 SNCA U73166.2
Type 2 Diabetes (T2D) (2018)	1.6	1	0	0.0	0.00	1.0e+00	PPIP5K2
High blood pressure	1.6	2	1	2.2	0.00	1.0e+00	MADD MAPT
Mouth/teeth dental problems	1.6	1	0	0.0	0.00	1.0e+00	MAPT
Standing height	1.6	13	9	20.0	-0.18	5.6e-01	AATK AS3MT INO80E MADD MAPT MC4R NCOA6 NEK4 PPIP5K2 PTCH1 RP11-165J3.6 RPS6KL1 SNCA
Birth weight of first child	1.6	1	0	0.0	0.00	1.0e+00	AS3MT
Number of full sisters	1.6	1	0	0.0	0.00	1.0e+00	CADM2
Forced expiratory volume in 1-second (FEV1), predicted	1.6	1	0	0.0	0.00	1.0e+00	PTCH1
Handedness (chirality/laterality): Left-handed	1.6	1	1	2.2	0.00	1.0e+00	MAPT
Ever had prostate specific antigen (PSA) test	1.6	1	0	0.0	0.00	1.0e+00	TMEM161B
Primary Biliary Cirrhosis	1.5	1	0	0.0	0.00	1.0e+00	PLCL2
Heel T-Score	1.5	9	4	8.9	-0.10	7.9e-01	ADCK3 DTD1 INO80E MADD MAPT NCOA6 RP11-165J3.6 SLC25A17 SPATS2
Hearing difficulty/problems: Yes	1.5	2	0	0.0	0.00	1.0e+00	MAPT MMAB
Noisy workplace	1.5	1	0	0.0	0.00	1.0e+00	MAPT
Pulse rate, automated reading	1.5	2	0	0.0	0.00	1.0e+00	KAT8 ORC4L
Comparative height size at age 10	1.5	7	3	6.7	-0.52	2.3e-01	INO80E KAT8 MAPT NEK4 PTCH1 RPS6KL1 SNCA
Hypertension (Self-reported)	1.5	1	0	0.0	0.00	1.0e+00	MADD
Medication: Blood pressure	1.5	1	1	2.2	0.00	1.0e+00	MAPT
Blood Eosinophil Count	1.4	6	4	8.9	-0.62	1.9e-01	INO80E MAPT NEK4 ORC4L PLCL2 SLC25A17
Allergy or Eczema	1.4	2	2	4.4	0.00	1.0e+00	PLCL2 SLC25A17
Heel bone mineral density (BMD) T-score, automated (left)	1.4	2	0	0.0	0.00	1.0e+00	ADCK3 MAPT
Hayfever, allergic rhinitis or eczema	1.4	1	0	0.0	0.00	1.0e+00	PLCL2
Illnesses of father: High blood pressure	1.4	1	0	0.0	0.00	1.0e+00	MADD
Vascular/heart problems diagnosed by doctor	1.4	1	0	0.0	0.00	1.0e+00	MADD
Rheumatoid Arthritis	1.3	1	0	0.0	0.00	1.0e+00	PPIP5K2
Cardiovascular Disease	1.3	2	0	0.0	0.00	1.0e+00	AS3MT RP11-85F14.5
Heel bone mineral density (BMD) T-score, automated (right)	1.3	2	0	0.0	0.00	1.0e+00	ADCK3 MAPT
Qualifications: A levels/AS levels or equivalent	1.3	2	0	0.0	0.00	1.0e+00	MAPT NDST3
Hypothyroidism (self reported)	1.2	1	1	2.2	0.00	1.0e+00	PPIP5K2
Hypothyroidism/myxoedema (self-reported)	1.2	1	0	0.0	0.00	1.0e+00	PPIP5K2
Breast Cancer	1.1	1	1	2.2	0.00	1.0e+00	MAPT
Blood Platelet Count	1.1	10	8	17.8	-0.06	8.7e-01	CREB3L4 KAT8 MADD MAN1A2 NCOA6 NEK4 RP11-78O7.2 RP11-85F14.5 RPS6KL1 U73166.2
Blood White Count	1.1	8	5	11.1	-0.43	2.8e-01	AATK MADD MAPT PPIP5K2 PTCH1 RP11-78O7.2 RP11-85F14.5 TMEM161B
Diastolic blood pressure, automated reading	1.1	1	0	0.0	0.00	1.0e+00	MADD

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Hippocampus	8	1.53	2.7
GTEx	Small Intestine Terminal Ileum	5	1.08	2.6
GTEx	Brain Frontal Cortex BA9	10	1.08	2.5
GTEx	Liver	10	1.40	2.5
GTEx	Ovary	11	1.21	2.5
GTEx	Brain Cortex	10	0.97	2.4
GTEx	Brain Putamen basal ganglia	5	0.80	2.4
GTEx	Cells EBV-transformed lymphocytes	16	1.13	2.4
GTEx	Colon Transverse	21	1.02	2.4
GTEx	Heart Atrial Appendage	13	0.82	2.4
GTEx	Pituitary	15	1.35	2.4
GTEx	Spleen	11	0.78	2.4
GTEx	Uterus	8	1.41	2.4
GTEx	Adipose Visceral Omentum	14	0.69	2.3
GTEx	Artery Coronary	15	1.27	2.3
GTEx	Brain Caudate basal ganglia	7	0.76	2.3
GTEx	Brain Nucleus accumbens basal ganglia	12	1.39	2.3
GTEx	Breast Mammary Tissue	15	0.76	2.3
GTEx	Breast Mammary Tissue (Female)	16	0.98	2.3
GTEx	Esophagus Gastroesophageal Junction	16	1.11	2.3
GTEx	Esophagus Muscularis	24	0.74	2.3
GTEx	Heart Left Ventricle	12	0.78	2.3
GTEx	Stomach	10	0.69	2.3
GTEx	Vagina	7	1.10	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	5	0.73	2.3
GTEx	Adrenal Gland	10	0.69	2.2
GTEx	Artery Aorta	23	0.77	2.2
GTEx	Brain Cerebellar Hemisphere	12	0.81	2.2
GTEx	Brain Cerebellum	15	0.76	2.2
GTEx	Brain Hypothalamus	5	0.85	2.2
GTEx	Breast Mammary Tissue (Male)	9	0.76	2.2
GTEx	Colon Sigmoid	15	1.03	2.2
GTEx	Esophagus Mucosa	24	0.72	2.2
GTEx	Lung	23	0.80	2.2
GTEx	Muscle Skeletal	18	0.62	2.2
GTEx	Pancreas	12	0.74	2.2
GTEx	Prostate	7	0.84	2.2
GTEx	Skin Not Sun Exposed Suprapubic	18	0.73	2.2
GTEx	Testis	19	0.60	2.2
GTEx	Thyroid	27	0.68	2.2
GTEx	Whole Blood	10	0.50	2.2
ROSMAP	Brain Pre-frontal Cortex	26	0.59	2.2
GTEx	Artery Tibial	19	0.51	2.1
GTEx	Cells Transformed fibroblasts	22	0.52	2.1
GTEx	Nerve Tibial	22	0.51	2.1
GTEx	Skin Sun Exposed Lower leg	22	0.61	2.1
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.55	2.1
The Cancer Genome Atlas	Glioblastoma Multiforme	7	0.69	2.1
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	12	0.48	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	4	0.58	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	7	0.66	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	7	0.55	2.1
GTEx	Adipose Subcutaneous	18	0.52	2.0
METSIM	Adipose	21	0.46	2.0
NTR	Blood	7	0.29	2.0
CommonMind	Brain Pre-frontal Cortex	14	0.26	2.0
The Cancer Genome Atlas	Colon Adenocarcinoma	6	0.29	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	14	0.51	2.0
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.44	2.0
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.36	2.0
The Cancer Genome Atlas	Lung Adenocarcinoma	14	0.48	2.0
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	11	0.69	2.0
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	5	0.30	2.0
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	8	0.61	2.0
The Cancer Genome Atlas	Stomach Adenocarcinoma	7	0.42	2.0
YFS	Blood	11	0.24	1.9
The Cancer Genome Atlas	Breast Invasive Carcinoma	14	0.32	1.9
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.46	1.9
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	17	0.42	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	11	0.26	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	16	0.35	1.9
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.9
The Cancer Genome Atlas	Thyroid Carcinoma	20	0.39	1.9
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	1.9